Mary K Hill1, Azin Kheirandish Pishkenari1, Taylor L Braunberger2, April W Armstrong3, Cory A Dunnick4. 1. University of Colorado School of Medicine, Aurora, Colorado. 2. University of North Dakota School of Medicine, Grand Forks, North Dakota. 3. Department of Dermatology, University of Southern California, Los Angeles, California. 4. Department of Dermatology, University of Colorado Denver, Aurora, Colorado; Dermatology Service, US Department of Veterans Affairs, Eastern Colorado Health Care System, Denver, Colorado. Electronic address: cory.dunnick@ucdenver.edu.
Abstract
BACKGROUND: A significant number of instruments exist that are aimed at quantifying atopic dermatitis (AD) outcomes. OBJECTIVE: We sought to assess recent trends in the use of disease severity and quality of life (QOL) outcome instruments in randomized controlled trials (RCTs) conducted on patients with AD between July 2010 and July 2015. METHODS: A total of 540 nonduplicate records were identified through searches of Scopus and Ovid MEDLINE. Included studies were RCTs conducted on humans with AD that were published in English between July 2010 and July 2015 and that reported the results of disease severity or QOL outcome measures. RESULTS: All of the 135 included studies assessed disease severity. Only 45 studies assessed QOL. Sixty-two disease severity measures and 28 QOL scales were identified. LIMITATIONS: This study was limited by its timeframe of 5 years and by the exclusion of non-RCTs and gray literature. CONCLUSION: Disease severity and QOL outcome measures are instrumental in evaluating AD treatment efficacy. The number of such tools used in RCTs on patients with AD continues to rise. Standardization of outcomes instruments is essential for comparability among studies and improved quality of evidence. Published by Elsevier Inc.
BACKGROUND: A significant number of instruments exist that are aimed at quantifying atopic dermatitis (AD) outcomes. OBJECTIVE: We sought to assess recent trends in the use of disease severity and quality of life (QOL) outcome instruments in randomized controlled trials (RCTs) conducted on patients with AD between July 2010 and July 2015. METHODS: A total of 540 nonduplicate records were identified through searches of Scopus and Ovid MEDLINE. Included studies were RCTs conducted on humans with AD that were published in English between July 2010 and July 2015 and that reported the results of disease severity or QOL outcome measures. RESULTS: All of the 135 included studies assessed disease severity. Only 45 studies assessed QOL. Sixty-two disease severity measures and 28 QOL scales were identified. LIMITATIONS: This study was limited by its timeframe of 5 years and by the exclusion of non-RCTs and gray literature. CONCLUSION: Disease severity and QOL outcome measures are instrumental in evaluating AD treatment efficacy. The number of such tools used in RCTs on patients with AD continues to rise. Standardization of outcomes instruments is essential for comparability among studies and improved quality of evidence. Published by Elsevier Inc.
Authors: Marissa T Ayasse; Adnan Ahmed; Maria L Espinosa; Christina J Walker; Muhammad Yousaf; Jacob P Thyssen; Jonathan I Silverberg Journal: Arch Dermatol Res Date: 2020-11-22 Impact factor: 3.017
Authors: Zarqa Ali; Kristina Melbardis Joergensen; Anders Daniel Andersen; Andrei Chiriac; Theis Bjerre-Christensen; Ionela Manole; Ana-Maria Dutei; Irina Deaconescu; Alina Suru; Adina Serban; Ari Pall Isberg; Priyanka Dahiya; Simon Francis Thomsen; John Robert Zibert Journal: JMIR Form Res Date: 2021-05-25
Authors: J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu Journal: Br J Dermatol Date: 2020-09-21 Impact factor: 9.302
Authors: J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu Journal: J Eur Acad Dermatol Venereol Date: 2020-09-01 Impact factor: 6.166